A Single Receptor, Two Diseases: Assembly Biosciences Reveals Phase 1a Data and $100 Million Plan for ABI-6250
26.05.2026 - 03:31:53 | boerse-global.de
Assembly Biosciences is banking on a single molecular target to address two distinct categories of liver disease — and the first human proof-of-concept data for its candidate ABI-6250 are due to land this week at the European Association for the Study of the Liver congress in Barcelona. The drug blocks the sodium-taurocholate cotransporting polypeptide (NTCP), a membrane protein on hepatocytes that serves as both the entry portal for hepatitis delta virus (HDV) and the primary transporter for bile acids. By shutting down NTCP, the company hopes to treat chronic HDV infections and, in parallel, the cholestatic conditions primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) — the latter of which still lacks any approved therapy.
On May 27, Edward J. Gane of the University of Auckland will present interim findings from a randomized, blinded Phase 1a study in healthy volunteers. The data cover safety, pharmacokinetics, and pharmacodynamics, and have already yielded a critical biomarker signal: dose-dependent increases in plasma bile acids that confirm NTCP inhibition is occurring in the target tissue. Chronic toxicology studies are complete, supporting the long-term dosing regimens planned for Phase 2. Assembly has also held a pre-IND meeting with the FDA for the cholestatic indications, which management described as constructive.
The expansion of ABI-6250’s clinical program beyond virology comes at a moment when the HDV competitive landscape has shifted. Gilead Sciences recently secured accelerated US approval for Hepcludex (bulevirtide) — itself an NTCP inhibitor — based on the Phase 3 MYR301 study, which posted a 48 percent response rate at 48 weeks. For Assembly, that approval validates the entry-inhibitor mechanism but also hands a significant head start to a much larger rival. HDV itself affects only about five percent of the 254 million people globally with chronic hepatitis B, making it a narrow but medically urgent market.
Should investors sell immediately? Or is it worth buying Assembly Biosciences?
Assembly’s own financial footing is solid enough to fund the next phase of development. The company beat first-quarter 2026 earnings estimates by $0.11 per share. More immediately, it has completed a $100 million public offering, placing roughly 3.36 million shares at $26.50 each together with pre-funded warrants for 415,000 additional shares. The transaction, led by Guggenheim Securities, UBS Investment Bank, and Mizuho, is expected to close on May 26. HC Wainwright, which rates the stock “Moderate Buy,” has set a price target of $48.70 — implying a 72 percent upside from the offering price.
With the capital in hand, Assembly has laid out a clear clinical timeline. A Phase 2 study in HDV is slated to begin in the fourth quarter of 2026, followed by a basket trial for PBC and PSC in the first quarter of 2027, pending regulatory feedback. The upcoming EASL data will be the first test of whether the NTCP mechanism can deliver on its biological promise across both viral and cholestatic indications. If the safety and biomarker profile holds, the expanded pipeline could emerge as a genuine value driver — not merely a strategic reaction to Gilead’s lead.
Ad
Assembly Biosciences Stock: New Analysis - 26 May
Fresh Assembly Biosciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
